Motilal Oswal remains positive on Blue Jet Healthcare amid signs of recovery in pharma intermediates, while retaining a Neutral stance on Exide despite a stronger-than-expected June-quarter performance.
Motilal Oswal remains positive on Blue Jet Healthcare amid signs of recovery in pharma intermediates, while retaining a Neutral stance on Exide despite a stronger-than-expected June-quarter performance.
<iframe src="https://hindustansphere.com/embed/cluster/2134bcf9fcaeb89490d2ce95d400b043fd2deb8b" width="100%" height="320" style="border:0;max-width:680px" loading="lazy" title="Blue Jet Healthcare, Exide Shares In Focus After Q1 Results; Motilal Oswal Bullish On One, Cautious On Other"></iframe>
